Emerging Superpowers of Clinical Research - Russia, India, China

28-29 May 2009, Amsterdam, Netherlands.
Faster patient recruitment and potential for cost savings are only a few of the factors attracting international sponsors to the emerging regions of clinical research. Countries like the Russian Federation, India and China offer similar attractions, as well as raising similar questions, when being considered as a location for clinical trials.

Similarities between these three countries include large patient pools enabling rapid recruitment due to massive treatment-naïve populations with diseases of both the developed and developing world. Russia, India and China are the next pace setters for pharmaceutical clinical trials, bringing both opportunities and challenges for the industry. The increasing inclusion of these markets in international trials indicates that leading Pharma and Biotech are recognising the advantages of conducting trials in these regions.

Aside from large patient populations, key benefits of these countries include: low cost of services, highly-competent labor pools and well equipped sites. However, local practices which differ from country to country, such as cultural, language, logistical, ethical and local regulatory requirements can make life challenging for companies performing clinical research. Specific issues faced by clinical trial operations across these three markets include protection of patients’ rights and safety, regulatory compliance, inconsistent data quality, lack of sufficient numbers of trained clinical researchers and even site saturation.

This event will examine in detail the opportunities in these unique markets which present the fastest global growth in clinical trials for timely, high-quality and cost-effective clinical development. Experienced speakers will help you understand the differing cultural and other aspects which are essential for successful conduct of clinical trials, including establishing of strong business relationships and ensuring trials’ compliance with ICH GCP Guidelines.

NextLevel Pharma's "Emerging SUPERPOWERS in Clinical Research" event will also provide dedicated, 1 on 1 partnering sessions enabling sponsor companies (Pharma, Biotech, Vaccine, Diagnostic and Medical device manufacturers) to meet with CROs, Central Labs, leading consultants, software and other clinical solution providers experienced in these growing markets to discuss potential partnerships.

For further information and registration, please visit:
https://www.nextlevelpharma.com/events/view/emerging_superpowers_of_clinical_research

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...